If ASC is required for GvHD by enhancing the function of pathogenic T cells [9], then therapeutically targeting the inflammasome receptor and/or caspase-1 may specifically eliminate the alloreactive T cell pool to improve GvHD outcomes without influencing Graft-versus-leukemia responses. This evidence concerns the gene CASP1 and graft versus host disease.